• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Sol-Gel Technologies Ltd.

    5/5/25 7:30:00 AM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLGL alert in real time by email
    6-K 1 zk2533108.htm 6-K


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 6-K
     
    Report of Foreign Private Issuer
    Pursuant to Rule 13a-16 or 15d-16
    Under the Securities Exchange Act of 1934
     
    For the month of May 2025
     
    Commission File Number 001-38367
     
    SOL-GEL TECHNOLOGIES LTD.
    (Translation of registrant’s name into English)
     
    7 Golda Meir Street
    Ness Ziona 7403650, Israel
    (Address of principal executive offices)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
     
    Form 20-F ☒     Form 40-F ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐
     

    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

    Reverse Split
     
    On May 1, 2025, Sol-Gel Technologies Ltd. (the “Company”) announced that it will effect a reverse share split (the “Reverse Split”) of the Company’s ordinary shares, par value NIS 0.1 per share, (the “Ordinary Shares”), at the ratio of 1-for-10. As a result of the Reverse Split, every ten (10) Ordinary Shares shall be consolidated into one (1) Ordinary Share. The Ordinary Shares will continue to trade on the Nasdaq Capital Market under the existing symbol “SLGL” and will begin trading on a split-adjusted basis when the market opens on May 5, 2025. The new CUSIP numbers for the Ordinary Shares following the Reverse Split will be M8694L 137.
     
    The Reverse Split was approved by the Company’s shareholders at the Company’s Special Meeting of Shareholders held on April 1, 2025, to be effected at the board of directors’ discretion within approved parameters, and the board of directors has approved the 1-for-10 ratio. In conjunction with the Reverse Split, the Company will also adjust the authorized share capital under the Company’s amended and restated articles of association, as currently in effect (the “Articles”), from 50,000,000 to 5,000,000 and adjust the par value from 0.1 NIS per share to 1.0 NIS per share.
     
    The Reverse Split will adjust the number of issued and outstanding Ordinary Shares of the Company from approximately 27,857,620 Ordinary Shares to approximately 2,785,762 Ordinary Shares (subject to any further adjustments based on the treatment of fractional shares). In accordance with the Company’s Articles, no fractional Ordinary Shares will be issued as a result of the Reverse Split and all fractional Ordinary Shares shall be rounded to the nearest whole Ordinary Share. Proportional adjustments also will be made to Ordinary Shares underlying outstanding options and warrants (with a reciprocal increase in the per share exercise price), restricted shares, restricted share units, and to the number of Ordinary Shares issued and issuable under the Company’s share incentive plans and certain existing agreements.
     
    On May 1, 2025, the Company issued a press release announcing the Reverse Split, a copy of which is furnished as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “Report”).
     
    This Report is incorporated by reference into the Company’s registration statements on Form S-8 (Registration Nos. 333-223915 and 333-270477), Form F-3 (Registration No 333-264190) and Form F-1 (File No. 333-270478), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
     
    2

    EXHIBIT INDEX
     
    Exhibit No.
     
     
    99.1

    Press Release dated May 1, 2025.
     
    3

     SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
     
    SOL-GEL TECHNOLOGIES LTD.
     
     
     
    Date:  May 5, 2025
    By:
    /s/ Eyal Ben-Or
     
     
    Eyal Ben-Or
     
     
    Chief Financial Officer
     

    4
    Get the next $SLGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLGL

    DatePrice TargetRatingAnalyst
    8/19/2024$6.00 → $4.00Strong Buy → Outperform
    Raymond James
    10/21/2022$5.50Hold
    Jefferies
    11/15/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    11/12/2021$23.00 → $21.00Strong Buy
    Raymond James
    7/28/2021$20.00 → $21.00Buy
    HC Wainwright & Co.
    7/12/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SLGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TWYNEO issued to SOL-GEL TECHNOLOGIES LTD

      Submission status for SOL-GEL TECHNOLOGIES LTD's drug TWYNEO (ORIG-1) with active ingredient TRETINOIN;BENZOYL PEROXIDE has changed to 'Approval' on 07/26/2021. Application Category: NDA, Application Number: 214902, Application Classification: Type 4 - New Combination

      7/27/21 10:39:03 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care